Filing Flows › Elevance Health (ELV) › Stock forecast & fair value
Elevance Health (ELV) stock forecast and fair value
Elevance Health (ELV) trades at $432.00. 21 analysts' median price target is $492.00 (+14%), from $406.00 to $523.00. Across 16 valuation methods the middle fair value is $356.49 (-17%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $422.45 | $580.05 | $1,079.53 | +34% |
| P/E vs peers, weighted | $316.14 | $505.38 | $647.32 | +17% |
| P/E vs peers, matched | $287.79 | $321.69 | $541.52 | -26% |
| Residual income | $225.10 | $233.70 | $242.81 | -46% |
| P/B vs ROE (insurer peers) | $102.85 | $398.48 | $694.11 | -8% |
| Analysts' price targets | $406.00 | $482.38 | $523.00 | +12% |
| Our model (Rotation forecast) | $288.99 | $404.08 | $565.01 | -6% |
| Shareholder yield (dividends + buybacks) | $301.33 | $356.49 | $436.38 | -17% |
| Justified P/B (Gordon growth) | $310.40 | $388.73 | $519.95 | -10% |
| Dividend discount (Gordon) | $147.26 | $184.42 | $246.68 | -57% |
Elevance Health's latest quarter
Elevance Health, Q3 2026: revenue $51.4B (+1% year over year), operating margin 2.5%, net earnings $1.3B, operating cash flow $1.3B. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ELV stock?
The median of 21 analysts' 12-month targets is $492.00, +14% from $432.00; the range is $406.00 to $523.00. The average rating is buy.
What is Elevance Health's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $131.04 and $580.05, with a middle value of $356.49 against a price of $432.00. Each method's assumptions are on the page.
Does Elevance Health usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is ELV stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.